💡 Bottom Line
The Novo vs. Lilly rivalry has cut GLP-1 prices by 50–70% in 18 months. Novo launched the Wegovy pill at $149. Lilly matched with Foundayo at $149. Lilly cut Zepbound vials to $299. Novo slashed list prices 50%. The beneficiary of this war? You.
Two pharmaceutical giants are fighting for dominance in the most lucrative drug market in history — and every move they make saves you money. Here's the timeline of the price war and what's coming next.
The Price War Timeline
| Date | Move | By | Impact |
|---|---|---|---|
| Nov 2025 | Trump "most favored nation" deals | Both | ~$350/mo self-pay programs launched |
| Nov 2025 | Wegovy/Ozempic self-pay at $349/mo | Novo | First sub-$500 brand-name pricing |
| Dec 2025 | Zepbound vials cut to $299/mo | Lilly | Undercut Novo on starting dose by $50 |
| Dec 2025 | Oral Wegovy FDA-approved | Novo | First GLP-1 pill |
| Jan 2026 | Oral Wegovy launches at $149/mo | Novo | Matched compounded pricing for first time |
| Feb 2026 | Novo sues Hims over compounded sema | Novo | Legal attack on compounding market |
| Feb 2026 | Novo announces 50% list price cut for Jan 2027 | Novo | List drops to $675/mo |
| Apr 2026 | Foundayo FDA-approved at $149/mo | Lilly | Matched Novo's pill pricing exactly |
| Apr 2026 | Zepbound KwikPen pricing at $299–449 | Lilly | New pen format expands access |
How This Helps You Right Now
The manufacturer price war has created a race to the bottom that benefits patients at every price tier:
- Brand-name pills: Two FDA-approved oral options at $149/month (unthinkable 18 months ago)
- Brand-name injectables: Zepbound vials at $299, Wegovy at $349 (down from $1,000+)
- Compounded providers: Forced to cut prices to $119–149/month to stay competitive
- Medicare: Both manufacturers committed to $50/month pricing for the Bridge program
What's Coming Next
- Jan 2027: Novo list prices drop to $675/month — biggest single price cut in GLP-1 history
- 2027: IRA-negotiated Medicare price: $274/month for Wegovy/Ozempic
- 2027–2028: 16+ new GLP-1 competitors entering the market (amycretin, survodutide, pemvidutide, and others)
- 2031–2032: Semaglutide patents expire in the US — generics become possible
Today's Best Prices
| Provider | Starting Price | Details |
|---|---|---|
| Get Thin MD | $119/mo | Check Price → Paid link |
| Yucca Health | $149/mo | Check Price → Paid link |
| Novi | $174/mo | Check Price → Paid link |
| Sesame Care | from $199 | Check Price → Paid link |
Key Takeaways
- The Novo vs. Lilly price war has cut GLP-1 costs by 50–70% since mid-2025
- Two FDA-approved pills now at $149/month (Wegovy + Foundayo)
- Compounded providers dropped to $119/month to compete
- Prices will continue falling: 50% list cuts in 2027, Medicare negotiated pricing, new competitors
- The best time to start GLP-1 treatment is now — prices are at historic lows
Compare All GLP-1 Prices
See today's lowest verified prices from vetted telehealth providers.
Compare Prices →Paid link · Compounded medications are not FDA-approved.